Alex Makhnin

A Phase 2 Basket Trial of Ado-Trastuzumab Emtansine for Patients with HER2 Amplified Cancers: A Non-Randomized Clinical Trial

Jessica C. Stuart, Winston Wong, Lauren Schoech, Alex Makhnin et autres

us (code pays fourni par la source)

Supplemental Figure 3 from Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas

Arielle Elkrief, Alex Makhnin, Khadeja A. Moses, Linda S. Ahn et autres

Supplemental Figure 2 from Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas

Arielle Elkrief, Alex Makhnin, Khadeja A. Moses, Linda S. Ahn et autres

Supplemental Figure 1 from Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas

Arielle Elkrief, Alex Makhnin, Khadeja A. Moses, Linda S. Ahn et autres

Supplementary Table 1 from Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas

Arielle Elkrief, Alex Makhnin, Khadeja A. Moses, Linda S. Ahn et autres

Supplemental Figure 4 from Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas

Arielle Elkrief, Alex Makhnin, Khadeja A. Moses, Linda S. Ahn et autres

A Phase II Study of Cabozantinib in Patients With MET-Altered Lung Cancers

Guilherme Harada, Fernando C. Santini, Clare Wilhelm, Rebecca W Repetti et autres

us, br (code pays fourni par la source)

Final results of a phase II study of cabozantinib in patients with MET -altered lung cancers.

Guilherme Harada, Fernando C. Santini, Rebecca W Repetti, Jason C. Chang et autres

us (code pays fourni par la source)

A phase 2 basket trial of ado-trastuzumab emtansine for patients with HER2 amplified cancers.

Jessica Ross, Bob T. Li, Lauren Schoech, Alan L. Ho et autres

us (code pays fourni par la source)

Data from A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer

Noura J. Choudhury, W. Victoria Lai, Alex Makhnin, Glenn Heller et autres

Data from A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer

Noura J. Choudhury, W. Victoria Lai, Alex Makhnin, Glenn Heller et autres

Supplementary Table 2 from A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer

Noura J. Choudhury, W. Victoria Lai, Alex Makhnin, Glenn Heller et autres